Navigation Links
Kibow Biotech Achieves Major Victory with India's IPAB Decision to Uphold 2009 Product Patent
Date:12/2/2013

NEWTOWN SQUARE, Pa., Dec. 2, 2013 /PRNewswire/ -- The landmark decision by India's top IP body, the Intellectual Property Appellate Board (IPAB), to uphold Kibow Biotech's key product patent No: 224100 granted in the year 2009 by the government of India is a major victory for a small biotech company based in Pennsylvania. 

This product patent entitled "Compositions for Augmenting Kidney Function" is a probiotic dietary supplement developed over a ten-year period with extensive R&D and clinical validation. The innovative product which sells as Renadyl™ (previously sold as Kibow® Biotics in USA and Canada only) received wide acclaim around the world including from top medical professionals, scientists and the company's distinguished Scientific Advisory Board (SAB) members (www.kibowbiotech.com).   

The revocation petition against two of Kibow's patents was filed by LaRenon Health Care, an Indian pharmaceutical firm. Kibow had sued LaRenon for infringement before the Madras High Court, alleging infringement of its patents. While this suit was dismissed for procedural irregularities, La Renon filed revocations before the IPAB challenging both the product patent (Patent No: 224100) and the Process Patent (No.205478) covering a novel method of augmenting kidney function.

While the IPAB, via an order of the Vice Chairman Hon'ble S. Usha and Technical Member (Patents) Hon'ble D.P.S Parmar, invalidated the weaker process patent, it upheld the product patent. When compared to a process patent, a product patent is infinitely more valuable as it permits the patentee to prevent third parties such as LaRenon from making a copy of the product, irrespective of the process that they use to arrive at the product.

In particular, the judges agreed with the contention of Kibow that "the invention covers a new and inventive composition comprising at least one probiotics bacteria of a certain kind, in a certain composition and along with other additives (such as vitamins, etc.) that confer synergistic impact, enabling the augmentation of kidney function". The company's management and its research and development team are fully convinced and believe that "by no stretch of imagination can this unique composition be labeled as mere admixture."

Patents covering the product/process formulation on the probiotic dietary food supplement formulation have already been obtained in Australia, Canada, China, Japan, and Korea, and are pending in the European Union. Kibow Biotech is represented in India by a leading Delhi-based IP law firm, Obhan and Associates, www.obhanandassociates.com   

About Kibow Biotech:  Founded in Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

For further information, contact:
Natarajan Ranganathan, PhD
Managing Director 
1 (610) 353-5130

Read more news from Kibow Biotech


'/>"/>
SOURCE Kibow Biotech
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Future of Pre- and Probiotics to be Discussed by Kibow Biotech Founder During SupplySide MarketPlace 2013 Global Expo & Conference
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
7. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today ... clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place ... on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE ... and the popularity of US Single Day Events (SDE) to organize a multiple-day ... 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry will ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
Breaking Biology Technology:
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
Breaking Biology News(10 mins):